Literature DB >> 34450228

Three months extended-release microspheres prepared by multi-microchannel microfluidics in beagle dog models.

Ju Hee Kim1, Choong Ho Ryu2, Chan Hee Chon3, Seyeon Kim4, Sangno Lee5, Ravi Maharjan6, Nam Ah Kim7, Seong Hoon Jeong8.   

Abstract

To evaluate in vivo drug release profiles in beagle dogs, finasteride-loaded PLGA microspheres were prepared using a novel method of IVL-PPF Microsphere® microfluidic device. Briefly, the dispersed phase (PLGA and finasteride in dichloromethane) was mixed with the continuous phase (0.25% w/v PVA aqueous solution) in the parallelized microchannels. After lyophilization, the diameter of the microspheres was around 40 μm (PLGA 7502A or 5002A) and around 30 µm (PLGA/PLA02A mixture). Their CV and span values suggested a narrow size distribution in repeated batch preparations. The in vivo drug release from the PLGA microspheres exhibited three substantial phases: an initial burst, a moderate release, and then a plateau. The microspheres based on PLGA 7502A (75:25 co-polymer) demonstrated extended drug release for around 1 month with a minimized initial burst release compared to PLGA 5002A (50:50 co-polymer). Moreover, the in vivo drug release profile in beagle dogs was proportionally related to the amount of drug loading. Furthermore, the addition of PLA02A into the fabrication of the microsphere synergistically extended the drug release up to 3 months. These results demonstrated the value of this method to achieve uniform microspheres and extend the drug release properties with interpretative in vivo PK profiles.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Extended drug release; Finasteride; IVL-PPF Microsphere®; Microfluidics; Microsphere; PLGA

Mesh:

Substances:

Year:  2021        PMID: 34450228     DOI: 10.1016/j.ijpharm.2021.121039

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  1 in total

1.  Effect of Bufalin-PLGA Microspheres in the Alleviation of Neuropathic Pain via the CCI Model.

Authors:  Lina Long; Wenwei Zhong; Liwei Guo; Jing Ji; Hong Nie
Journal:  Front Pharmacol       Date:  2022-06-13       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.